Title:
A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma
Indication:
Melanoma
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Dura Trem EV MIBC Ca
View
Description: D910PC00001: A Phase III Randomized Open-Label Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination with Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 HR+/HER2- BC (OVELIA)
View
Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 HR+/HER2- BC (OVELIA)
View
Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)
Indication:
Breast Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 HR+/HER2- BC (OVELIA)
View
Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 HR+/HER2- BC (OVELIA)
View
Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 HER2+/ER+ BC
View
Description: A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 HER2+/ER+ BC
View
Description: A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571)
Indication:
Breast Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 HER2+/ER+ BC
View
Description: A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 HER2+/ER+ BC
View
Description: A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 DAto-DXd PD1/PD L1 BC (TROPION Breast02)
View
Description: D926PC00001: A Phase III Open-label Randomized Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02).
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 DAto-DXd PD1/PD L1 BC (TROPION Breast02)
View
Description: D926PC00001: A Phase III Open-label Randomized Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02).
Indication:
Breast Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 DAto-DXd PD1/PD L1 BC (TROPION Breast02)
View
Description: D926PC00001: A Phase III Open-label Randomized Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02).
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 DAto-DXd PD1/PD L1 BC (TROPION Breast02)
View
Description: D926PC00001: A Phase III Open-label Randomized Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02).
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Sac Gov Pemb vs PC BC (ASCENT-04)
View
Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (GS-US-592-6173)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Sac Gov Pemb vs PC BC (ASCENT-04)
View
Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (GS-US-592-6173)
Indication:
Breast Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Sac Gov Pemb vs PC BC (ASCENT-04)
View
Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (GS-US-592-6173)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Sac Gov Pemb vs PC BC (ASCENT-04)
View
Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (GS-US-592-6173)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Sac GOv vs PC BC (ASCENT-03)
View
Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1 (GS-US-592-6238)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Sac GOv vs PC BC (ASCENT-03)
View
Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1 (GS-US-592-6238)
Indication:
Breast Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Sac GOv vs PC BC (ASCENT-03)
View
Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1 (GS-US-592-6238)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Sac GOv vs PC BC (ASCENT-03)
View
Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1 (GS-US-592-6238)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
View
Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
View
Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
Indication:
Breast Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
View
Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
View
Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD)
View
Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD)
View
Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)
Indication:
Breast Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD)
View
Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD)
View
Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 robotic Hysterectomy ROCC
View
Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)
Indication:
Cervical Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 robotic Hysterectomy ROCC
View
Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)
Indication:
Cervical Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 robotic Hysterectomy ROCC
View
Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)
Indication:
Cervical Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: III
Title:
Ph3 robotic Hysterectomy ROCC
View
Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)
Indication:
Cervical Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: III
Title:
Ph3 robotic Hysterectomy ROCC
View
Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)
Indication:
Cervical Cancer
Location:
Texas Oncology-Austin North Next Oncology
Phase: III
Title:
Ph1b/3 Bema + Nivo Gastric GEJ FGFR2b
View
Description: (20210098) A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph1b/3 Bema + Nivo Gastric GEJ FGFR2b
View
Description: (20210098) A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 EpiOvarian FallTube PriPeritoneal
View
Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 EpiOvarian FallTube PriPeritoneal
View
Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 EpiOvarian FallTube PriPeritoneal
View
Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: III
Title:
Ph3 EpiOvarian FallTube PriPeritoneal
View
Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: III
Title:
Ph3 EpiOvarian FallTube PriPeritoneal
View
Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Austin North Next Oncology
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Austin North Next Oncology
Phase: III
Title:
Ph1b/3 Bema + Nivo Gastric GEJ FGFR2b
View
Description: (20210098) A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)
Indication:
Gastric Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph1b/3 Bema + Nivo Gastric GEJ FGFR2b
View
Description: (20210098) A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)
Indication:
Gastric Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3b oral asciminib v. nilotinib in newly dx Phl. Chrom+ CML in Chronic phase
View
Description: A phase IIIb multi-center open-label randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (CABL001J12302)
Indication:
Leukemia
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3b oral asciminib v. nilotinib in newly dx Phl. Chrom+ CML in Chronic phase
View
Description: A phase IIIb multi-center open-label randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (CABL001J12302)
Indication:
Leukemia
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3b oral asciminib v. nilotinib in newly dx Phl. Chrom+ CML in Chronic phase
View
Description: A phase IIIb multi-center open-label randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (CABL001J12302)
Indication:
Leukemia
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3b oral asciminib v. nilotinib in newly dx Phl. Chrom+ CML in Chronic phase
View
Description: A phase IIIb multi-center open-label randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (CABL001J12302)
Indication:
Leukemia
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph 3 Durv vs. plbo SBRT NSCLC (PAC 4)
View
Description: D9103C00001: A Phase III Randomized Placebo-controlled Double-blind Multi-center International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph 3 Durv vs. plbo SBRT NSCLC (PAC 4)
View
Description: D9103C00001: A Phase III Randomized Placebo-controlled Double-blind Multi-center International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph 3 Durv vs. plbo SBRT NSCLC (PAC 4)
View
Description: D9103C00001: A Phase III Randomized Placebo-controlled Double-blind Multi-center International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph 3 Durv vs. plbo SBRT NSCLC (PAC 4)
View
Description: D9103C00001: A Phase III Randomized Placebo-controlled Double-blind Multi-center International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-Round Rock
Phase: III
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-Round Rock
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor
View
Description: A Randomized Open-Label Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (GS-US-626-6216)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor
View
Description: A Randomized Open-Label Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (GS-US-626-6216)
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor
View
Description: A Randomized Open-Label Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (GS-US-626-6216)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor
View
Description: A Randomized Open-Label Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (GS-US-626-6216)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR
View
Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR
View
Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR
View
Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004
Indication:
Lung Cancer
Location:
Texas Oncology-Round Rock
Phase: III
Title:
STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR
View
Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR
View
Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 SGN-B6A vs docetaxel NSCLC
View
Description: A randomized phase 3 open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer (SGN-B6A-002)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 SGN-B6A vs docetaxel NSCLC
View
Description: A randomized phase 3 open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer (SGN-B6A-002)
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 SGN-B6A vs docetaxel NSCLC
View
Description: A randomized phase 3 open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer (SGN-B6A-002)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 SGN-B6A vs docetaxel NSCLC
View
Description: A randomized phase 3 open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer (SGN-B6A-002)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Study of AK112 or Placebo + Pemtrexed & Carboplatin EGFR NSCLC
View
Description: A Randomized Double-blind Multi-center Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi) (AK112-301)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Study of AK112 or Placebo + Pemtrexed & Carboplatin EGFR NSCLC
View
Description: A Randomized Double-blind Multi-center Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi) (AK112-301)
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Study of AK112 or Placebo + Pemtrexed & Carboplatin EGFR NSCLC
View
Description: A Randomized Double-blind Multi-center Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi) (AK112-301)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Study of AK112 or Placebo + Pemtrexed & Carboplatin EGFR NSCLC
View
Description: A Randomized Double-blind Multi-center Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi) (AK112-301)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)
View
Description: A Randomized Controlled Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous NSCLC (HARMONi-3)(SMT112-3003)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)
View
Description: A Randomized Controlled Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous NSCLC (HARMONi-3)(SMT112-3003)
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)
View
Description: A Randomized Controlled Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous NSCLC (HARMONi-3)(SMT112-3003)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)
View
Description: A Randomized Controlled Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous NSCLC (HARMONi-3)(SMT112-3003)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 EpiOvarian FallTube PriPeritoneal
View
Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 EpiOvarian FallTube PriPeritoneal
View
Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)
Indication:
Ovarian Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 EpiOvarian FallTube PriPeritoneal
View
Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: III
Title:
Ph3 EpiOvarian FallTube PriPeritoneal
View
Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: III
Title:
Ph3 EpiOvarian FallTube PriPeritoneal
View
Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin North Next Oncology
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Ovarian Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin North Next Oncology
Phase: III
Title:
Ph3 EpiOvarian FallTube PriPeritoneal
View
Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 EpiOvarian FallTube PriPeritoneal
View
Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 EpiOvarian FallTube PriPeritoneal
View
Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: III
Title:
Ph3 EpiOvarian FallTube PriPeritoneal
View
Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: III
Title:
Ph3 EpiOvarian FallTube PriPeritoneal
View
Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Austin North Next Oncology
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Austin North Next Oncology
Phase: III
Title:
PH3 Place Capi+ Doce Place+ Doce mCRPC
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (D361EC00001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
PH3 Place Capi+ Doce Place+ Doce mCRPC
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (D361EC00001)
Indication:
Prostate Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
PH3 Place Capi+ Doce Place+ Doce mCRPC
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (D361EC00001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
PH3 Place Capi+ Doce Place+ Doce mCRPC
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (D361EC00001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Apalutamide Monotherapy Castration-Sensitive Prostate Cancer (mCSPC) LIBERTAS
View
Description: A Phase 3 Open-label Randomized Prospective Study of Apalutamide with Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) following PSA Response in Participants with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (56021927PCR3020)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Central
Phase: III
Title:
Ph3 Apalutamide Monotherapy Castration-Sensitive Prostate Cancer (mCSPC) LIBERTAS
View
Description: A Phase 3 Open-label Randomized Prospective Study of Apalutamide with Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) following PSA Response in Participants with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (56021927PCR3020)
Indication:
Prostate Cancer
Location:
Texas Oncology-South Austin
Phase: III
Title:
Ph3 Apalutamide Monotherapy Castration-Sensitive Prostate Cancer (mCSPC) LIBERTAS
View
Description: A Phase 3 Open-label Randomized Prospective Study of Apalutamide with Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) following PSA Response in Participants with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (56021927PCR3020)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Midtown
Phase: III
Title:
Ph3 Apalutamide Monotherapy Castration-Sensitive Prostate Cancer (mCSPC) LIBERTAS
View
Description: A Phase 3 Open-label Randomized Prospective Study of Apalutamide with Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) following PSA Response in Participants with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (56021927PCR3020)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III